Pathware
Pathware is a company focused on improving healthcare by integrating computational microscopy and AI at the Point-of-Care. Their flagship product, Bioptic™, offers real-time biopsy quality assessment. This technology addresses critical issues in diagnostics: 20-25% of biopsies are inadequate, leading to patient stress and repeat procedures. Pathologists lose significant billing potential when performing on-site evaluations compared to lab work. Hospitals incur substantial costs due to repeat procedures and unnecessary surgeries, estimated at $1.6 billion annually. Furthermore, 92% of thyroid surgeries following indeterminate biopsies are found to be unnecessary, costing the insurance industry $165 million annually. Pathware aims to enable earlier and more precise disease diagnosis and treatment, ultimately saving lives.
Pathware
Pathware is a company focused on improving healthcare by integrating computational microscopy and AI at the Point-of-Care. Their flagship product, Bioptic™, offers real-time biopsy quality assessment. This technology addresses critical issues in diagnostics: 20-25% of biopsies are inadequate, leading to patient stress and repeat procedures. Pathologists lose significant billing potential when performing on-site evaluations compared to lab work. Hospitals incur substantial costs due to repeat procedures and unnecessary surgeries, estimated at $1.6 billion annually. Furthermore, 92% of thyroid surgeries following indeterminate biopsies are found to be unnecessary, costing the insurance industry $165 million annually. Pathware aims to enable earlier and more precise disease diagnosis and treatment, ultimately saving lives.
TL;DR
Product: Bioptic — point-of-care digital pathology system for real-time biopsy quality assessment
Problem addressed: Reduces inadequate biopsies and repeat procedures that increase costs and patient burden
Latest known funding: Series A, Apr 2022 (led by UnityPoint Health Ventures and Level Eight Ventures)
Headquarters: Golden, Colorado, USA
Company Overview
Problem Domain
Diagnostic pathology — biopsy quality assessment and point-of-care diagnostics
Industry
Medical technology / Digital pathology
Funding Track Record
7000000.00
Reported oversubscribed Series A in April 2022
Investor Signal
“Series A led by healthcare-focused and venture investors (UnityPoint Health Ventures; Level Eight Ventures) with additional individual and institutional participants”